초록 ▼

The invention relates to a multiparticulate drug form suitable for uniform release of an active pharmaceutical ingredient in the small intestine and in the large intestine, comprising at least two forms of pellets A and B which comprise an active pharmaceutical ingredient in the core and have differ

The invention relates to a multiparticulate drug form suitable for uniform release of an active pharmaceutical ingredient in the small intestine and in the large intestine, comprising at least two forms of pellets A and B which comprise an active pharmaceutical ingredient in the core and have different polymer coatings which determine the release of the active ingredient at different pH values, characterized in that pellet form A is provided with an inner polymer coating which enables continuous release of active ingredient, and has an outer enteric coating which rapidly dissolves above about pH 5.5, and pellet form B is provided with a polymer coating which, in the USP release test, releases less than 20% of the active ingredient at pH 6.8 in 6 hours and releases more than 50% of the active ingredient at pH 7.2 in 6 hours. The invention additionally relates to a process for producing the multiparticulate drug form and to the use of pellet forms A and B for producing the drug form.

대표청구항 ▼

1. A multiparticulate drug form comprising at least pellet form A and pellet form B, wherein each of said pellet forms comprises an active pharmaceutical ingredient and at least one polymer coating, wherein the polymer coating of pellet form A is different from the polymer coating of pellet form B,w

1. A multiparticulate drug form comprising at least pellet form A and pellet form B, wherein each of said pellet forms comprises an active pharmaceutical ingredient and at least one polymer coating, wherein the polymer coating of pellet form A is different from the polymer coating of pellet form B,wherein pellet form A comprises an inner polymer coating and an outer enteric coating which rapidly dissolves above about pH 5.5, and pellet form B comprises a different polymer coating which, in the USP release test, releases less than 20% of the active pharmaceutical ingredient at pH 6.8 in 6 hours and releases more than 50% of the active pharmaceutical ingredient at pH 7.2 in 6 hours, wherein said multiparticulate drug form is capable of uniformly releasing the active pharmaceutical ingredient in the small intestine and large intestine, and wherein the polymer coating of pellet form A and pellet form B determines the release of the active pharmaceutical ingredient at different pH, wherein the active pharmaceutical ingredient is an aminosalicylate, a sulphonamide, a hormone, a peptide, an interferon, or a glucocorticoid. 2. The multiparticulate drug form according to claim 1, wherein the enteric polymer coating of pellet form A comprises an acidic group-containing (meth)acrylate copolymer, shellac, HPMCP (hydroxypropylmethylcellulose phthalate), CAP (cellulose acetate phthalate), HIPMC-AS (hydroxypropylmethylcellulose acetate succinate) or polyvinyl acetate phthalate.3. The multiparticulate drug form according to claim 2, wherein the enteric polymer coating is a (meth)acrylate copolymer comprising 40 to 60% by weight of polymerized methacrylic acid and 60 to 40% by weight ofpolymerized methyl methacrylate or ethyl acrylate.4. The niultiparticulate drug form according to claim 1, wherein the inner polymer coating of pellet form A comprises a (meth)acrylate copolymer comprising free-radical polymerized C1- to C4-alkyl esters of acrylic or methacrylic acid and (meth)acrylate monomers with a quatemary anunonium group in the alkyl radical, a (meth)acrylate copolymer of 20 to 40% by weight of polymerized ethyl acrylate and 60 to 80% by weight of polymerized methyl methacrylate, ethylcellulose or polyvinyl acetate.5. The multiparticulate drug form according to claim 4, wherein the inner polymer coating of pellet form A comprises a (meth)acrylate copolymer of 85 to less than 93% by weight of polymerized units of C1- to C4-alkyl esters of acrylic or methacrylic acid and more than 7 to 15% by weight of polymerized (meth)acrylate monomers with a quaternary animonium group in the alkyl radical.6. The multiparticulate drug form according to claim 1, wherein the different polymer coating of pellet form B comprises a (meth)acrylate copolymer comprising 60 to 95% by weight free-radical polymerized C1- to C4-alkyl esters of acrylic or methacrylic acid and 5 to 40% by weight (meth)acrylate monomers with an acidic group in the alkyl radical.7. The multiparticulate drug form according to claim 6, wherein the different polymer coating of pellet form B comprises a (meth)acrylate copolymer comprising 10 to 30% by weight of polymerized units of methyl methacrylate, 50 to 70% by weight methyl acrylate and 5 to 15% by weight methacrylic acid.8. The multiparticulate drug form according to claim 6, wherein pellet form B further comprises an inner polymer coating.9. The multiparticulate drug form according to claim 1, wherein the active pharmaceutical ingredient is 5-aminosalicylic acid, olsalazine, sulfalazine, prednisone or budesonide.10. A process for producing the multiparticulate drug form according to claim 1, comprisingcoating cores comprising at least one active pharmaceutical ingredient with an inner polymer coating and an outer enteric coating to form pellet form A, coating cores comprising at least one active pharmaceutical ingredient with at least one different polymer coating to form pellet form B, mixing said pellet forms A and B, and forming the multiparticulate drug form by introducing the mixed pellet forms A and B into a capsule or compressing the mixed pellet forms A and B in the presence of one or more excipients. 11. The multiparticulate drug form according to claim 1, wherein the multiparticulate drug form is capable of uniformly releasing the active ingredient in a pH range of from 6.8 to 7.2.12. The multiparticulate drug form according to claim 1, wherein the multiparticulate drug form is capable of treating Crohn's disease or ulcerative colitis.13. The multiparticulate drug form according to claim 1, wherein each of said pellet forms A and B comprise the same active pharmaceutical ingredient.14. The process according to claim 10, wherein each of said pellet forms A and B comprise the same active pharmaceutical ingredient.15. A method comprisingadministering an active pharmaceutical ingredient to a human, wherein the active pharmaceutical ingredient is released in the small intestine and the large intestine, wherein the active pharmaceutical ingredient is present in a multiparticulate drug form comprising at least pellet form A and pellet form B, wherein the pellet form A comprises an inner polymer coating and an outer enteric coating which rapidly dissolves above about pH 5.5, and wherein pellet form B comprises a polymer coating which releases less than 20% of the active pharmaceutical ingredient at a pH of 6.8 in 6 hours and releases more than 50% of the active ingredient at a pH of 7.2 in 6 hour, wherein the polymer coating of pellet form A is different from the polymer coating of pellet form B, and wherein the active pharmaceutical ingredient is an aminosalicylate, a suiphonamide, a hormone, a peptide, an interferon, or a glucocorticoid. 16. The method of claim 15, wherein an active pharmaceutical ingredient is administered to treat Crohn's disease or ulcerative colitis.17. The method according to claim 15, wherein each of said pellet forms A and B comprise the same active pharmaceutical ingredient.